# The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS

> **NCT04651855** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Polski Bank Komorek Macierzystych JSC (PBKM)** · enrollment: 20 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Mesenchymal stem cells isolated from Wharton's jelly

## Key facts

- **NCT ID:** NCT04651855
- **Lead sponsor:** Polski Bank Komorek Macierzystych JSC (PBKM)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-02
- **Primary completion:** 2022-03-08
- **Final completion:** 2023-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2022-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04651855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04651855, "The Evaluation of the Effect of Mesenchymal Stem Cells on the Immune System of Patients With ALS". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT04651855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*